MK-9470

CAS No. 945850-36-2

MK-9470( MK9470 )

Catalog No. M16778 CAS No. 945850-36-2

MK-9470 is a potent, selective cannabinoid CB1 receptor (CB1R) inverse agonist with IC50 of 0.7 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    MK-9470
  • Note
    Research use only, not for human use.
  • Brief Description
    MK-9470 is a potent, selective cannabinoid CB1 receptor (CB1R) inverse agonist with IC50 of 0.7 nM.
  • Description
    MK-9470 is a potent, selective cannabinoid CB1 receptor (CB1R) inverse agonist with IC50 of 0.7 nM, 18F MK-9470 has been developed for use in human brain imaging.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    MK9470
  • Pathway
    GPCR/G Protein
  • Target
    Cannabinoid Receptor
  • Recptor
    Cannabinoid Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    945850-36-2
  • Formula Weight
    471.59
  • Molecular Formula
    C29H33N3O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CC1=CN=C(C=C1)OC(C)(C)C(=O)NC(C)C(CC2=CC=C(C=C2)OCCF)C3=CC=CC(=C3)C#N
  • Chemical Name
    N-[(2S,3S)-3-(3-cyanophenyl)-4-(4-ethoxyphenyl)butan-2-yl]-2-methyl-2-[(5-methylpyridin-2-yl)oxy]propanamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Burns HD, et al. Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9800-5. 2. Van Laere K, et al. J Nucl Med. 2008 Mar;49(3):439-45. 3. Gérard N, et al. J Mol Neurosci. 2010 Oct;42(2):162-7.
molnova catalog
related products
  • CB1/2 agonist 3

    CB1/2 agonist 3 is a competitive and potent CB1/CB2 agonist with high affinity for hCB1 and hCB2 and can be used to study neurological disorders.

  • LDK1229

    LDK1229 is a novel potent, selective cannabinoid CB1 receptor inverse agonist with Ki of 220 nM.

  • EHP-101

    VCE-004.8 is a specific dual agonist of PPARγ and CB2 receptor with potent anti-inflammatory activity. VCE-004.8 attenuates adipogenesis and prevents diet-induced obesity.